X4 Pharmaceuticals Net Income

As reflected in current metrics, X4 Pharmaceuticals posts the 14-period RSI reading of 51, consistent with balanced price action. A midpoint RSI reading suggests neither buyers nor sellers hold a decisive advantage at this juncture.Current projections place Total Revenue at 1.47 Million, representing a change of 99.54%. Last year, X4 Pharmaceuticals recorded Total Revenue of 2.94 Million. Current projections place Gross Profit at 1.66 Million, representing a change of 4.76%. Last year, X4 Pharmaceuticals recorded Gross Profit of 1.58 Million. As of this month (March), Gross Profit Margin is projected to grow to 0.91, while Pretax Profit Margin is projected to decrease toward -17.54 .

X4 Pharmaceuticals Total Revenue

1.47 Million

Examining X4 Pharmaceuticals's income statement, balance sheet, and cash flow together gives a multi-dimensional view of its financial health and valuation potential. Key drivers are highlighted below:Over one hundred nineteen fundamental trends are available for X4 Pharmaceuticals, supporting both time-series and peer-group analysis. A careful review of X4 Pharmaceuticals' regular performance relative to the period from 2010 to 2026 can reveal whether underlying fundamentals are strengthening or weakening. As of this month (March), Enterprise Value is projected to grow to approximately 160.6 M, while Market Cap is projected to decrease toward slightly above 69.7 M. Equity Screeners complement this analysis by enabling custom filters across sectors and regions.

		Last Reported	Projected for Next Year
	Net Loss	-86.8 M	-82.4 M
	Net Loss	-33.7 M	-35.4 M
	Net Loss	-33.7 M	-35.4 M
	Net Loss	-5.03	-5.28
	Net Income Per E B T	1.16	1.11

As of this month (March), Net Loss is projected to grow to approximately -82.4 M. In addition to that, Net Loss is expected to decrease toward approximately -35.4 M.